Author:
Tomás-Velázquez Alejandra,Sanmartin-Jiménez Onofre,Garcés Joan R.,Rodríguez-Prieto Manuel A.,Ruiz-Salas Verónica,De Eusebio-Murillo Esther,Miñano-Medrano Román,Escutia-Muñoz Begoña,Flórez-Menéndez Ángeles,Artola-Igarza Juan L.,Alfaro-Rubio Alberto,Gil Pilar,Delgado-Jiménez Yolanda,Sanchez-Schmidt Julia M.,Allende-Markixana Irati,Alonso-Pacheco María L.,García-Bracamonte Beatriz,De la Cueva-Dobao Pablo,Navarro-Tejedor Raquel,Ciudad-Blanco Cristina,Carnero-González Lucía,Vázquez-Veiga Hugo,Cano-Martínez Natividad,Vilarrasa-Rull Eva,Sanchez-Sambucety Pedro,López-Estebaranz José L.,Botella-Estrada Rafael,Gonzalez-Sixto Beatriz,Martorell-Calatayud Antonio,Morales-Gordillo Victoriano,Toll-Abelló Agustí,Ocerin-Guerra Izascun,Mayor-Arenal Matías,Suárez-Fernández Ricardo,Sainz-Gaspar Laura,Descalzo Miguel A.,García-Doval Ignacio,Redondo Pedro
Abstract
Randomized studies to assess the efficacy of Mohs micrographic surgery in basal cell and squamous cell carcinomas are limited by methodological and ethical issues and a lack of long follow-up periods. This study presents the “real-life” results of a nationwide 7-years cohort on basal cell carcinoma and squamous cell carcinoma treated with Mohs micrographic surgery. A prospective cohort was conducted in 22 Spanish centres (from July 2013 to February 2020) and a multivariate analysis, including characteristics of patients, tumours, surgeries and follow-up, was performed. A total of 4,402 patients followed up for 12,111 patient-years for basal cell carcinoma, and 371 patients with 915 patient-years of follow-up for squamous cell carcinoma were recruited. Risk factors for recurrence included age, non-primary tumours and more stages or unfinished surgeries for both tumours, and immunosuppression for squamous cell carcinoma. Incidence rates of recurrence were 1.3 per 100 person-years for basal cell carcinoma (95% confidence interval 1.1–1.5) and 4.5 for squamous cell carcinoma (95% confidence interval 3.3–6.1), being constant over time (0–5 years). In conclusion, follow-up strategies should be equally intense for at least the first 5 years, with special attention paid to squamous cell carcinoma (especially in immunosuppressed patients), elderly patients, non-primary tumours, and those procedures requiring more stages, or unfinished surgeries.
Publisher
Medical Journals Sweden AB
Subject
Dermatology,General Medicine